Glucocorticoid-Mediated Astrocytic Lactate Release and Chronic Postsurgical Pain: Mechanistic Insights

Study Background and Research Question

Chronic postsurgical pain (CPSP) remains a clinically significant and poorly understood complication, affecting 10–50% of patients after common surgical procedures according to Li et al. (2026). CPSP is not simply a transient consequence of tissue injury, but a distinct syndrome characterized by persistent pain at the surgical site for months or even years. Despite its prevalence, the cellular and molecular mechanisms underlying the development and maintenance of CPSP are not fully resolved. Recent advances have highlighted the importance of neuron-glia metabolic coupling, particularly the role of astrocyte-derived l-lactate, in modulating neuronal excitability and plasticity during pain states. The central research question addressed by the reference study is: How does glucocorticoid signaling influence astrocytic l-lactate release in the spinal dorsal horn, and what is the impact of this mechanism on the development and persistence of chronic postsurgical pain?

Key Innovation from the Reference Study

A major innovation of this work lies in the mechanistic linking of stress-induced glucocorticoid receptor (GR) activation to astrocytic metabolic reprogramming and l-lactate release, ultimately driving spinal neuronal sensitization and chronic pain. The study not only establishes a causative pathway from surgical trauma to persistent mechanical allodynia but also identifies astrocytic l-lactate as a critical modulator of spinal neuronal intrinsic excitability—distinct from synaptic transmission. This paradigm shifts the focus from neurons alone to the metabolic and signaling contributions of spinal astrocytes in chronic pain states.

Methods and Experimental Design Insights

The authors utilized a multifaceted experimental approach in a rat model of CPSP induced by skin/muscle incision and retraction (SMIR), a method validated to evoke long-lasting mechanical allodynia.

• Spinal dorsal horn l-lactate levels and astrocyte activation were quantified post-SMIR using biochemical and immunohistochemical assays.
• To interrogate the metabolic pathway, pharmacological inhibitors were employed:
  • 4-dideoxy-1,4-imino-D-arabinitol (DAB): Inhibits glycogenolysis in astrocytes.
  • Acetazolamide: Inhibits carbonic anhydrase, modulating intracellular HCO3−.
  • Bithionol: Inhibits soluble adenylyl cyclase (sAC).
• Chemogenetic inhibition of spinal astrocytes was performed using Designer Receptors Exclusively Activated by Designer Drugs (DREADDs), providing cell-type-specific suppression of astrocyte activity.
• Electrophysiological recordings from spinal lamina I-II neurons assessed the impact of exogenous l-lactate on neuronal firing and synaptic transmission.
• Endocrine manipulation included adrenalectomy (ADX) to ablate glucocorticoid production, thus probing the upstream hormonal drivers of the observed phenomena.

This comprehensive design allowed the dissection of cell-type, molecular, and circuit-level contributions to CPSP.

Protocol Parameters

• SMIR surgery: Induce skin/muscle incision and retraction in adult rats to model CPSP.
• Pharmacological inhibition: Administer DAB (glycogenolysis inhibitor), acetazolamide (carbonic anhydrase inhibitor), or bithionol (sAC inhibitor) prior to behavioral and biochemical assays to interrogate astrocytic metabolic pathways.
• Chemogenetic inhibition: Inject AAV vectors encoding inhibitory DREADDs under astrocyte-specific promoters into the spinal dorsal horn; activate with a selective actuator such as CNO as appropriate.
• Adrenalectomy: Surgically remove adrenal glands to eliminate systemic glucocorticoid production; monitor plasma hormone levels to confirm efficacy.
• Electrophysiology: Prepare transverse spinal cord slices for whole-cell patch-clamp recordings from lamina I-II neurons; apply exogenous l-lactate and record neuronal firing rates and synaptic currents.

Core Findings and Why They Matter

The study provides several key findings:

• SMIR triggers persistent mechanical allodynia in rats, accompanied by activation of spinal astrocytes and a marked elevation of l-lactate in the dorsal horn.
• Inhibition of astrocytic glycogenolysis, carbonic anhydrase, or sAC each prevented the development of allodynia and reduced lactate accumulation, implicating the astrocyte metabolic axis in CPSP pathogenesis.
• Chemogenetic inhibition of spinal astrocytes (via DREADDs) suppressed mechanical allodynia and l-lactate elevation, directly linking astrocyte activity to pain maintenance.
• Exogenous l-lactate significantly increased the firing rate of spinal lamina I-II neurons, but did not impact excitatory synaptic transmission, suggesting a unique role for lactate in modulating neuronal intrinsic excitability rather than synaptic efficacy.
• SMIR-induced increases in plasma glucocorticoids were necessary for both pain development and spinal lactate rise—adrenalectomy abolished these effects, confirming the upstream role of glucocorticoid signaling.

These results underscore a novel feedforward mechanism: surgical trauma elevates glucocorticoids, which activate astrocytic GRs, triggering metabolic changes that drive l-lactate release and neuronal sensitization in the spinal cord. This positions astrocytic lactate metabolism as a promising target for therapeutic intervention in chronic pain.

Comparison with Existing Internal Articles

The application of chemogenetic tools, such as DREADDs, to selectively modulate astrocyte function in vivo is a rapidly advancing area of neuroscience. Several internal resources discuss the reliability and specificity of designer ligands such as Clozapine N-oxide (CNO) for such workflows:

• The article "Clozapine N-oxide: Precision Chemogenetic Actuator for Neuroscience" details how CNO’s inertness and selectivity make it an indispensable chemogenetic actuator for DREADDs-based neuronal activity modulation, as employed in the current reference study.
• Similarly, "Clozapine N-oxide (CNO): Chemogenetic Reliability for Neu..." provides guidance for optimizing GPCR signaling research using CNO, aligning with the reference paper’s approach to astrocyte-specific inhibition.

These internal analyses reinforce the importance of validated chemogenetic actuators for robust and reproducible neuron-glia manipulation in pain models and broader neuroscience research.

Limitations and Transferability

While the study provides compelling mechanistic evidence in a rodent model, several limitations must be considered:

• The use of SMIR in rats, while translationally relevant, may not fully recapitulate the complexity of human CPSP, particularly regarding interspecies differences in astrocyte metabolism and glucocorticoid signaling.
• Although the chemogenetic inhibition approach offers high cell-type specificity, potential off-target effects of viral delivery and actuator compounds (including CNO) require careful control.
• The study focuses on male rats, so sex-specific differences in CPSP pathophysiology remain unaddressed.
• Direct clinical translation will necessitate evaluation of astrocytic lactate targeting strategies in human tissues and the development of safe, selective modulators.

Nonetheless, the elucidated pathway provides a strong conceptual framework for future translational research on glial modulation in chronic pain.

Research Support Resources

For researchers aiming to replicate or extend these findings, chemogenetic tools remain essential for cell-type-specific modulation of neuronal and glial function. Clozapine N-oxide (CNO) (SKU A3317) is a widely used, biologically inert DREADDs activator suitable for in vivo modulation of astrocyte or neuronal activity in rodent models. Product information indicates that CNO is highly pure and stable under recommended storage conditions, facilitating reliable outcomes in neuroscience research tool applications. For further details and best practices, consult both the product dossier and scenario-driven guidance provided in internal articles linked above.